← Back to Screener
NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)
Price$0.75
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-44.89%
Price vs S&P 500 (4W)-14.75%
VGM Score28.23
Market Capitalization$26.52M
All Metrics
Book Value / Share (Quarterly)$0.11
P/TBV (Annual)1.56x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.44
Price vs S&P 500 (YTD)-10.62%
EPS (TTM)$-0.62
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-0.62
EPS (Annual)$-0.44
ROI (Annual)-395.74%
Cash / Share (Quarterly)$0.15
ROA (Last FY)-222.93%
EBITD / Share (TTM)$-0.62
ROE (5Y Avg)-244.31%
Cash Flow / Share (Annual)$-0.44
P/B Ratio10.27x
P/B Ratio (Quarterly)10.74x
Net Income / Employee (Annual)$-695,300
Net Interest Coverage (TTM)-326.21x
ROA (TTM)-841.92%
EPS Incl Extra (Annual)$-0.44
Current Ratio (Annual)2.21x
Quick Ratio (Quarterly)2.17x
3-Month Avg Trading Volume0.15M
52-Week Price Return-56.39%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.12
52-Week High$2.60
EPS Excl Extra (Annual)$-0.44
CapEx CAGR (5Y)-4.36%
26-Week Price Return-36.97%
Quick Ratio (Annual)2.17x
13-Week Price Return-12.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.21x
Enterprise Value$23.14M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.15
3-Month Return Std Dev62.11%
Net Income / Employee (TTM)$-989,600
ROE (Last FY)-395.74%
Net Interest Coverage (Annual)-276.79x
EPS Basic Excl Extra (Annual)$-0.44
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.62
ROI (TTM)-395.28%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.48
Price vs S&P 500 (52W)-80.76%
Year-to-Date Return-2.46%
5-Day Price Return-7.71%
EPS Normalized (Annual)$-0.44
ROA (5Y Avg)-219.60%
Month-to-Date Return-8.68%
EBITD / Share (Annual)$-0.43
LT Debt / Equity (Annual)2.62x
ROI (5Y Avg)-242.73%
EPS Basic Excl Extra (TTM)$-0.62
P/B Ratio (Annual)10.71x
Book Value / Share (Annual)$0.11
Price vs S&P 500 (13W)-20.42%
Beta1.55x
Revenue / Share (TTM)$0.00
ROE (TTM)-395.28%
52-Week Low$0.63
mGradeD
vgmGradeD
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.11
4.10
4.10
4.11
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NRSNNeuroSense Therapeutics Ltd. Ordinary Shares | — | — | D | $0.75 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
NeuroSense Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases including ALS, Alzheimer's disease, and Parkinson's disease. Its lead candidate, PrimeC, is a novel extended-release oral formulation combining two FDA-approved generic drugs—ciprofloxacin and celecoxib—in a proprietary fixed-dose combination designed to treat these conditions.